Atopic dermatitis Control Tool

Terms and conditions – consent

ADCT terms of use

Atopic Dermatitis Control Tool (ADCT) has been scientifically validated to assess atopic dermatitis control status in adult and adolescent patients (12 years and older). To use ADCT correctly, a patient must answer all six ADCT questions by selecting the most appropriate answer. Patients should use ADCT in their own language.

ADCT was developed to facilitate patient-physician discussion on control of atopic dermatitis. ADCT is not intended to replace the physician’s medical judgment in diagnosing and treating the patient.

The user acknowledges and accepts that they are not entitled to amend, modify, condense, adapt, reorganise the tool on any medium whatsoever, in any way whatsoever, even minor, without Sanofi Genzyme’s and Regeneron’s prior specific written consent.

Use in individual clinical practice:

Users must ensure that ADCT is used in the context and with the standards it has been designed and validated for.

Use in scientific studies, clinical trials or research projects:

If you are planning to use ADCT in a clinical study, please use the following link to request the correct version of ADCT and the copyright from MAPI Research Trust: https://eprovide.mapi-trust.org/instruments/atopic-dermatitis-control-tool

You will be asked to complete a request form describing the intended use of the tool. The information provided with this form helps to ensure that ADCT is used in the context and with the standards it has been designed and validated for.